SCYNEXIS INC
Business
SCYNEXIS, Inc. is a biopharmaceutical company developing innovative antifungal therapeutics for severe rare fungal infections. The company's proprietary "fungerps" platform comprises a novel class of antifungal agents (triterpenoids and glucan synthase inhibitors) with activity against multidrug-resistant fungal pathogens. Its lead approved product, ibrexafungerp (BREXAFEMME), was licensed to GSK for vulvovaginal candidiasis treatment; its second-generation candidate SCY-247 is in Phase 1 development for invasive candidiasis and fungal infection prevention. SCYNEXIS markets through partnerships with GSK, Hansoh, R-Pharm, and others across North America, Europe, Asia, and Russia.
Summary from 10-K filed 2026-03-04
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue | 21 | 4 | 140 | 5 | 13 | |
| Research and development | 22 | 26 | 31 | 27 | 24 | |
| Selling, general and administrative | 14 | 14 | 21 | 63 | 50 | |
| Total operating expenses | 37 | 41 | 67 | 91 | 74 | |
| Loss from operations | −16 | −37 | 73 | −86 | −61 | |
| Amortization of debt issuance costs and discount | 312,000 | 2 | 3 | 2 | 1 | |
| Interest income | −2 | −4 | −4 | −1 | −24,000 | |
| Interest expense | 173,000 | 828,000 | 3 | — | — | |
| Other income | 0 | −235,000 | 0 | −3,000 | −13,000 | |
| Warrant liability fair value adjustment | −6 | −14 | 3 | −22 | −30 | |
| Derivative liability fair value adjustment | 0 | −196,000 | 154,000 | −1 | −1 | |
| Total other income | −7 | −16 | 5 | −18 | −25 | |
| Loss before taxes | −9 | −21 | 67 | −68 | −36 | |
| Income tax expense | 0 | −200,000 | −100,000 | 5 | 3 | |
| Net loss | −9 | −21 | 67 | −63 | −33 | |
| Net loss per share - basic | −0.17 | −0.44 | 1.4 | −1.47 | −1.25 | |
| Net loss per share - diluted | −0.17 | −0.44 | 1.39 | −1.47 | −1.25 | |
| Weighted average common shares outstanding - basic | 50 | 49 | 48 | 43 | 26 | |
| Weighted average common shares outstanding - diluted | 50 | 49 | 48 | 43 | 26 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 21 | 16 | 34 | 46 | 104 | |
| Short-term investments (Note 3) | 19 | 43 | 40 | 28 | 0 | |
| Prepaid expenses and other current assets (Note 4) | 263,000 | 2 | 6 | 3 | 4 | |
| License agreement receivable | 0 | 753,000 | 2 | 0 | — | |
| License agreement contract asset | 0 | 10 | 19 | 0 | — | |
| Restricted cash | 80,000 | 435,000 | 380,000 | 55,000 | 0 | |
| Total current assets | 40 | 72 | 102 | 79 | 109 | |
| Investments (Note 3) | 16 | 16 | 24 | 0 | — | |
| Deferred offering costs | 533,000 | 417,000 | 175,000 | 73,000 | 150,000 | |
| Restricted cash | 109,000 | 109,000 | 163,000 | 163,000 | 218,000 | |
| Operating lease right-of-use asset (Note 6) | 2 | 2 | 2 | 3 | 3 | |
| Total assets | 59 | 91 | 128 | 88 | 120 | |
| Accounts payable | 2 | 5 | 7 | 6 | 8 | |
| Accrued expenses (Note 5) | 3 | 4 | 7 | 6 | 6 | |
| Deferred revenue, current portion | 200,000 | 2 | 1 | 0 | — | |
| Operating lease liability, current portion (Note 6) | 483,000 | 407,000 | 340,000 | 282,000 | 70,000 | |
| Convertible debt and derivative liability (Note 6) | 0 | 14 | 0 | — | — | |
| Total current liabilities | 6 | 24 | 16 | 18 | 14 | |
| Deferred revenue | 0 | 1 | 3 | 0 | — | |
| Warrant liability | 2 | 8 | 22 | 19 | 18 | |
| Operating lease liability (Note 6) | 2 | 2 | 3 | 3 | 3 | |
| Total liabilities | 10 | 36 | 55 | 85 | 79 | |
| Commitments and contingencies | — | — | — | — | — | |
| Preferred stock, $0.001 par value, authorized 5,000,000 shares as of December 31, 2025 and 2024; 0 shares issued and outstanding as of December 31, 2025 and 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.001 par value, 150,000,000 shares authorized as of December 31, 2025 and 2024; 43,541,510 and 37,973,991 shares issued and outstanding as of December 31, 2025, and 2024, respectively | 46,000 | 41,000 | 40,000 | 36,000 | 32,000 | |
| Additional paid-in capital | 434 | 432 | 428 | 425 | 401 | |
| Accumulated deficit | −385 | −377 | −355 | −422 | −359 | |
| Total stockholders equity | 49 | 55 | 73 | 3 | 41 | |
| Total liabilities and stockholders equity | 59 | 91 | 128 | 88 | 120 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net (loss) income | −9 | −21 | 67 | −63 | −33 | |
| Stock-based compensation expense | 3 | 3 | 3 | 4 | 2 | |
| Accretion of investment discount | −474,000 | −1 | −1 | −309,000 | 0 | |
| Noncash operating lease expense for right-of-use asset | 326,000 | 272,000 | 230,000 | 207,000 | 198,000 | |
| Prepaid expenses and other current assets, deferred costs, and other | 2 | 3 | −3 | 2 | 2 | |
| License agreement contract asset | 10 | 10 | −19 | 0 | — | |
| License agreement receivable | 753,000 | 2 | −2 | 0 | — | |
| Accounts payable | −2 | −3 | 1 | −1 | 3 | |
| Accrued expenses | −1 | −4 | 2 | −70,000 | — | |
| Deferred revenue | −3 | −979,000 | 4 | 0 | — | |
| Other liabilities and other | −407,000 | −339,000 | −6 | 2 | — | |
| Net cash used in operating activities | −5 | −24 | 60 | −80 | −55 | |
| Purchase of investments | −19 | −36 | −85 | −27 | 0 | |
| Maturity of investments | 43 | 43 | 51 | 0 | — | |
| Net cash provided by investing activities | 24 | 6 | −35 | −27 | −1 | |
| Proceeds from common stock issued | 5,000 | 0 | 0 | 47 | 39 | |
| Payment of convertible debt | −14 | 0 | — | — | — | |
| Payments of deferred offering costs | −226,000 | −195,000 | −135,000 | — | — | |
| Proceeds from employee stock purchase plan issuances | 51,000 | 56,000 | 42,000 | 18,000 | 22,000 | |
| Net cash used in financing activities | −14 | −139,000 | −37 | 49 | 67 | |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 5 | −18 | −11 | −59 | 11 | |
| Cash paid for interest | 420,000 | 840,000 | 3 | 5 | 2 | |
| Cash received for interest | 2 | 3 | 4 | 1 | 24,000 | |
| Deferred offering and issuance costs included in accounts payable | 0 | 110,000 | 40,000 | 0 | 430,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is SCYNEXIS INC's CIK number?
SCYNEXIS INC's SEC CIK number is 0001178253 (1178253). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find SCYNEXIS INC's SEC filings?
All of SCYNEXIS INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did SCYNEXIS INC last report earnings?
SCYNEXIS INC (SCYX) most recently filed an earnings 8-K with the SEC on Mar 28, 2024, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0000950170-24-038015). This is SCYNEXIS INC's most recent earnings filing of record — not a forecast of its next earnings date.
What is SCYNEXIS INC's most recent earnings 8-K?
SCYNEXIS INC's latest earnings 8-K (Item 2.02) was filed Mar 28, 2024 under accession 0000950170-24-038015. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View SCYNEXIS INC's latest earnings 8-K →
Look up any company's CIK number →